Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy
暂无分享,去创建一个
John Trachtenberg | Michael A S Jewett | Laurence H Klotz | K. Siminovitch | J. Trachtenberg | L. Klotz | S. Narod | A. Toi | V. Venkateswaran | M. Jewett | L. Sugar | A. Loblaw | R. Nam | Linda Sugar | Joan Sweet | J. Sweet | Steven A Narod | Robert K Nam | Ants Toi | Andrew Loblaw | Kathy Siminovitch | William W Zhang | Seamus Teahan | Vasundara Venkateswaran | William W. Zhang | S. Teahan
[1] E. Diamandis,et al. Human Tissue Kallikrein 5 Is a Member of a Proteolytic Cascade Pathway Involved in Seminal Clot Liquefaction and Potentially in Prostate Cancer Progression* , 2006, Journal of Biological Chemistry.
[2] H. Koistinen,et al. Novel Peptide Inhibitors of Human Kallikrein 2* , 2006, Journal of Biological Chemistry.
[3] J. Trachtenberg,et al. The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy , 2005, Clinical Cancer Research.
[4] J. Clements,et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.
[5] Stig Nordling,et al. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue , 2005, The Prostate.
[6] E. Kawinski,et al. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. , 2005, Neoplasia.
[7] J. Clements,et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.
[8] Danny Vesprini,et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[9] M. Province,et al. 19 Classification methods for confronting heterogeneity , 2001 .
[10] M. Province,et al. Classification methods for confronting heterogeneity. , 2001, Advances in genetics.
[11] J. Trachtenberg,et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W. Catalona,et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.
[13] E. Diamandis,et al. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. , 1999, Clinical chemistry.
[14] M. Saedi,et al. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor‐1 , 1999, International journal of cancer.
[15] C. Lazure,et al. Prostatic kallikrein hK2, but not prostate‐specific antigen (hK3), activates single‐chain urokinase‐type plasminogen activator , 1997, International journal of cancer.
[16] R. Kurkela,et al. Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. , 1997, Clinical chemistry.